These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25617244)

  • 1. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
    Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
    J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Target Vascular Effects of Cholesteryl Ester Transfer Protein Inhibitors Involve Redox-Sensitive and Signal Transducer and Activator of Transcription 3-Dependent Pathways.
    Rios FJ; Lopes RA; Neves KB; Camargo LL; Montezano AC; Touyz RM
    J Pharmacol Exp Ther; 2016 May; 357(2):415-22. PubMed ID: 26941168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
    Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
    J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of CETP inhibition.
    Duivenvoorden R; Fayad ZA
    Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for cholesteryl ester transfer protein inhibition.
    Hewing B; Fisher EA
    Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
    Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
    J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
    Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1606-1617. PubMed ID: 28911944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
    Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
    Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.